Evidence map›Paper›PMID 26674787›Full record

ArticleIntegrative cancer therapies2017

B-Cell Disorders and Curcumin.

Terry Golombick, Terrence H Diamond, Arumugam Manoharan, Rajeev Ramakrishna

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Integrative cancer therapies, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. The Anti-Leukemic Activity of Natural Compounds.Molecules (Basel, Switzerland) · 2021
    Review
  3. Review
  4. Curcumin as a therapeutic agent in leukemia.Journal of cellular physiology · 2019
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Terry Golombick1 St George Hospital, Sydney, New South Wales, Australia.
Terrence H Diamond1 St George Hospital, Sydney, New South Wales, Australia.
Arumugam Manoharan2 University of Wollongong, Wollongong, NSW, Australia.
Rajeev Ramakrishna2 University of Wollongong, Wollongong, NSW, Australia.
St George Hospital · AUUniversity of Wollongong · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clinical studies with patients with early hematological malignancies (ie, monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or stage 0/1 chronic lymphocytic leukemia) suggest that early intervention with curcumin, derived from the spice turmeric, may lead to prolonged survival and delay in progressive disease in some of these patients.

Indexed as

B-LymphocytesCurcumaCurcuminDisease ProgressionHematologic DiseasesHumansCurcumincurcuminintegrative medicinemonoclonal gammopathy of undetermined significancesmoldering myelomastage 0/1 chronic lymphocytic leukemia

Identifiers

PMID26674787
PMCPMC5759937
OpenAlexW2199776754

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.